EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Preclinical Development of Antisense Oligonucleotides to Rescue Aberrant Splicing Caused by an Ultrarare ABCA4 Variant in a Child with Early-Onset Stargardt Disease

Nuria Suárez-Herrera iD, Catherina H Z Li, Nico Leijsten, Dyah W Karjosukarso iD, Zelia Corradi iD, Femke Bukkems, Lonneke Duijkers, Frans P M Cremers, Carel B Hoyng iD, Alejandro Garanto iD, Rob W J Collin iD

Cells · 29.03.2024 · 13 (7) · 601

DOI: 10.3390/cells13070601 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Cells, online erschienen am 29.03.2024. Verfasst von Nuria Suárez-Herrera und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Human Genetics, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands. Hauptthemen laut MEDLINE: Oligonucleotides, Antisense, ATP-Binding Cassette Transporters. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Foundation Fighting Blindness, European Union’s Horizon 2020 research and innovation program Marie Sklodowska-Curie Innovative Training Network (ITN) StarT, Foundation Fighting Blindness USA Project Program Award.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Precision medicine is rapidly gaining recognition in the field of (ultra)rare conditions, where only a few individuals in the world are affected. Clinical trial design for a small number of patients is extremely challenging, and for this reason, the development of N-of-1 strategies is explored to accelerate customized therapy design for rare cases. A strong candidate for this approach is Stargardt disease (STGD1), an autosomal recessive macular degeneration characterized by high genetic and phenotypic heterogeneity. STGD1 is caused by pathogenic variants in ABCA4, and amongst them, several deep-intronic variants alter the pre-mRNA splicing process, generally resulting in the insertion of pseudoexons (PEs) into the final transcript. In this study, we describe a 10-year-old girl harboring the unique deep-intronic ABCA4 variant c.6817-713A>G. Clinically, she presents with typical early-onset STGD1 with a high disease symmetry between her two eyes. Molecularly, we designed antisense oligonucleotides (AONs) to block the produced PE insertion. Splicing rescue was assessed in three different in vitro models: HEK293T cells, fibroblasts, and photoreceptor precursor cells, the last two being derived from the patient. Overall, our research is intended to serve as the basis for a personalized N-of-1 AON-based treatment to stop early vision loss in this patient.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Oligonucleotides, AntisenseATP-Binding Cassette TransportersHumansFemaleChildStargardt DiseaseHEK293 CellsIntrons

Stichwörter der Autor:innen

ABCA4N-of-1RNA therapyStargardt diseaseantisense oligonucleotidepseudoexonsplicing modulation

Substanzen

Oligonucleotides, AntisenseATP-Binding Cassette TransportersABCA4 protein, human

Autor:innen und Institutionen

  • Department of Human Genetics, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands.
  • Department of Ophthalmology, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands.
  • Dutch Center for RNA Therapeutics, 2311 EZ Leiden, The Netherlands.
  • Department of Pediatrics, Amalia Children's Hospital, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands.

ORCID-Profile: Nuria Suárez-Herrera, Dyah W Karjosukarso, Zelia Corradi, Carel B Hoyng, Alejandro Garanto, Rob W J Collin

Förderung

  • Foundation Fighting Blindness
  • European Union’s Horizon 2020 research and innovation program Marie Sklodowska-Curie Innovative Training Network (ITN) StarT
  • Foundation Fighting Blindness USA Project Program Award
  • Translational Research Acceleration Program (TRAP) of the Foundation Fighting Blindness USA

Zitieren

APA

Suárez-Herrera, N., Li, C. H. Z., Leijsten, N., Karjosukarso, D. W., Corradi, Z., Bukkems, F., Duijkers, L., Cremers, F. P. M., Hoyng, C. B., Garanto, A., & Collin, R. W. J. (2024). Preclinical Development of Antisense Oligonucleotides to Rescue Aberrant Splicing Caused by an Ultrarare ABCA4 Variant in a Child with Early-Onset Stargardt Disease. Cells, 13(7), 601. https://doi.org/10.3390/cells13070601

Vancouver

Suárez-Herrera N, Li CHZ, Leijsten N, Karjosukarso DW, Corradi Z, Bukkems F, et al. Preclinical Development of Antisense Oligonucleotides to Rescue Aberrant Splicing Caused by an Ultrarare ABCA4 Variant in a Child with Early-Onset Stargardt Disease. Cells. 2024;13(7):601. doi:10.3390/cells13070601

BibTeX
@article{SurezHerrera2024,
  author = {Suárez-Herrera, Nuria and Li, Catherina H Z and Leijsten, Nico and Karjosukarso, Dyah W and Corradi, Zelia and Bukkems, Femke and Duijkers, Lonneke and Cremers, Frans P M and Hoyng, Carel B and Garanto, Alejandro and Collin, Rob W J},
  title = {Preclinical Development of Antisense Oligonucleotides to Rescue Aberrant Splicing Caused by an Ultrarare ABCA4 Variant in a Child with Early-Onset Stargardt Disease},
  journal = {Cells},
  year = {2024},
  volume = {13},
  number = {7},
  pages = {601},
  doi = {10.3390/cells13070601}
}
Kostenlos starten →